Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

inhibitor mitiperstat failed to improve quality of life or functional capacity in heart failure with mid-range to preserved ejection fraction (HFmrEF, HFpEF), the phase II ENDEAVOR trial showed.

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

The challenge for Bayer will be carving out a role for Kerendia in mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF) heart failure alongside SGLT2 inhibitors – AstraZeneca's Farxiga ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Steroidal mineralocorticoid receptor antagonists (MRA) have proven benefits in HF with reduced ejection fraction (HFrEF), but their efficacy in HFmrEF/HFpEF has not been conclusively established.

BOSTON, MA—Tirzepatide improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, no matter how much excess body weight they have, according to an analysis ...

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...